Seattle Genetics to Present at the Barclays Global Healthcare Conference 2018

BOTHELL, Wash.--(BUSINESS WIRE)-- Seattle Genetics, Inc. (NASDAQ: SGEN) announced today that management will present at the Barclays Global Healthcare Conference 2018 on Wednesday, March 14, 2018 at 10:45 a.m. Eastern Time. The presentation will be webcast live and available for replay from Seattle Genetics’ website at www.seattlegenetics.com in the Investors section.

About Seattle Genetics

Seattle Genetics is an innovative biotechnology company dedicated to improving the lives of people with cancer through targeted therapies. The company’s industry-leading antibody-drug conjugate (ADC) technology harnesses the targeting ability of antibodies to deliver cell-killing agents directly to cancer cells. Seattle Genetics commercializes ADCETRIS® (brentuximab vedotin) for the treatment of several types of CD30-expressing lymphomas. The company is also advancing a robust pipeline of novel therapies for solid tumors and blood-related cancers designed to address significant unmet medical needs and improve treatment outcomes for patients. More information can be found at www.seattlegenetics.com and follow @SeattleGenetics on Twitter.

View source version on businesswire.com: http://www.businesswire.com/news/home/20180313005322/en/

Seattle Genetics, Inc.
Investors:
Peggy Pinkston, 425-527-4160
[email protected]
or
Media:
Tricia Larson, 425-527-4180
[email protected]

Source: Seattle Genetics, Inc.

You May Also Be Interested In

• Antengene Announces 2026 Interim Results: Achieves First‑Ever Profitability and Accelerates Value Creation Through Innovative R&D
• Solana Unchained Emerges as a Closely Watched Solana Presale Following Product Ecosystem Reveal
• Benz Announces A$150m Placement to Accelerate Delivery of Glenburgh Maiden Resource